Patient Profile: A 66-Year-Old with IgG Kappa MM

Opinion
Video

Binod Dhakal, MD, presents the case of a 66-year-old patient with IgG kappa multiple myeloma, and the panel discusses treatment considerations and decisions.

Video content above is prompted by the following questions:

  • Following this review of a 66-year-old patient with IgG kappa multiple myeloma, what therapies are available and how would you approach making a treatment decision?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“Every patient [with multiple myeloma] should be offered CAR T before they’re offered a bispecific, with some rare exceptions,” said Barry Paul, MD.
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.